166 related articles for article (PubMed ID: 35128858)
1. Prognostic value of complete metabolic response on ¹⁸F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer.
Chung YS; Kim Y; Kim HS; Lee JY; Kang WJ; Kim S; Kim SW
J Gynecol Oncol; 2022 May; 33(3):e28. PubMed ID: 35128858
[TBL] [Abstract][Full Text] [Related]
2. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
3. Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer.
Chung YS; Kim HS; Lee JY; Kang WJ; Nam EJ; Kim S; Kim SW; Kim YT
Cancer Res Treat; 2020 Oct; 52(4):1211-1218. PubMed ID: 32599990
[TBL] [Abstract][Full Text] [Related]
4. Prognostic utility of FDG PET/CT in advanced ovarian, fallopian and primary peritoneal high-grade serous cancer patients before and after neoadjuvant chemotherapy.
Watanabe M; Nakamoto Y; Ishimori T; Saga T; Kido A; Hamanishi J; Hamanaka Y; Togashi K
Ann Nucl Med; 2020 Feb; 34(2):128-135. PubMed ID: 31768818
[TBL] [Abstract][Full Text] [Related]
5.
Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
[No Abstract] [Full Text] [Related]
6. Prognostic value of
Han S; Choi JY
Breast Cancer Res; 2020 Oct; 22(1):119. PubMed ID: 33129348
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
[TBL] [Abstract][Full Text] [Related]
8. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
9. Preoperative PET/CT score can predict incomplete resection after debulking surgery for advanced serous ovarian cancer better than CT score, MTV, tumor markers and hematological markers.
Wang J; Liu L; Pang H; Liu L; Jing X; Li Y
Acta Obstet Gynecol Scand; 2022 Nov; 101(11):1315-1327. PubMed ID: 35979992
[TBL] [Abstract][Full Text] [Related]
10. The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer.
Lian W; Liu C; Gu B; Zhang J; Lu L; Pan H; Yao Z; Wang M; Song S; Zhang Y; Yang Z
Nucl Med Commun; 2020 Mar; 41(3):280-287. PubMed ID: 32032193
[TBL] [Abstract][Full Text] [Related]
11. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Chen X
Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of extended cycles of neoadjuvant chemotherapy in patients with advanced ovarian cancer in terms of prognosis and surgical outcomes.
Kim NK; Suh DH; Kim K; Kim YB; No JH
PLoS One; 2023; 18(4):e0284753. PubMed ID: 37083873
[TBL] [Abstract][Full Text] [Related]
13. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
[TBL] [Abstract][Full Text] [Related]
14.
Liu S; Feng Z; Wen H; Jiang Z; Pan H; Deng Y; Zhang L; Ju X; Chen X; Wu X
Jpn J Radiol; 2018 Sep; 36(9):544-550. PubMed ID: 29943313
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implication of the metastatic lesion-to-ovarian cancer standardised uptake value ratio in advanced serous epithelial ovarian cancer.
Chung HH; Lee M; Kim HS; Kim JW; Park NH; Song YS; Cheon GJ
Eur Radiol; 2017 Nov; 27(11):4510-4515. PubMed ID: 28593431
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral heterogeneity in
Molina-García D; García-Vicente AM; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Tello-Galán MJ; Soriano-Castrejón Á; Pérez-García VM
Ann Nucl Med; 2018 Jul; 32(6):379-388. PubMed ID: 29869770
[TBL] [Abstract][Full Text] [Related]
17. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
18. Preoperative omental metastasis-related maximum standardized fluorine-18-fluorodeoxyglucose uptake value can predict chemosensitivity and recurrence in advanced high-grade serous ovarian cancer patients.
Sun Y; Liu S; Feng Z; Cheng J; Lu L; Wang M; Yuan H; Xu J; Zhang Y
Nucl Med Commun; 2018 Aug; 39(8):761-767. PubMed ID: 30001265
[TBL] [Abstract][Full Text] [Related]
19. Can pretreatment
Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of [
Mirshahvalad SA; Seyedinia SS; Huemer F; Schweighofer-Zwink G; Koch O; Hitzl W; Weiss L; Emannuel K; Greil R; Pirich C; Beheshti M
Eur J Radiol; 2023 Jun; 163():110843. PubMed ID: 37119707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]